DNA methylation signatures of sporadic colorectal cancer with microsatellite instability.
Summary
This study investigated DNA methylation profiles in 259 sporadic colorectal cancers, aiming to identify microsatellite instability (MSI)-associated signatures beyond the CIMP phenotype and MLH1 promoter hypermethylation. Researchers discovered 656 differentially methylated CpG sites linked to MSI, including hypermethylation of LRP6, GSK3B, and CDK12, genes involved in WNT signaling and transcriptional regulation. The study also revealed heterogeneity within MSI CRCs, with co-occurrence of MLH1 and TXNRD1 promoter hypermethylation. Furthermore, anatomical location was found to be a major determinant of the CRC methylome, contributing to improved molecular stratification of the disease.
Analysis
🔴 CLINIQUE: This research refines the molecular stratification of colorectal cancer (CRC) by identifying DNA methylation signatures associated with microsatellite instability (MSI) beyond established markers. The discovery of hypermethylation in genes such as LRP6, GSK3B, and CDK12 could serve as prognostic or predictive biomarkers for MSI patient subgroups, justifying phase II clinical trials to evaluate their utility in therapeutic selection or monitoring, with a potential clinical impact within 3-5 years for better personalized treatments. 🟢 BIOMOL: The study employed epigenome-wide DNA methylation profiling using the Illumina EPICv2 array on 259 sporadic CRC samples. It led to the discovery of 656 differentially methylated CpG sites associated with MSI, independent of CIMP and MLH1 hypermethylation, including hypermethylation of the LRP6, GSK3B, and CDK12 promoters. These discoveries, based on tumor samples, pave the way for validation of these markers in clinical tests to refine diagnosis and prognosis. 🔵 BIOINFO: The bioinformatics analysis involved rigorous adjustment for tumor purity, anatomical location, and subsequently MLH1 promoter methylation and CIMP status, to delineate methylation changes specifically associated with MSI. This methodological approach, which controls for known confounding factors, is crucial for the robustness of the results and the advancement of molecular stratification, potentially by improving epigenetic data interpretation pipelines in clinical settings.